Upgrading respiratory care with digital medicines
AMIKO
Digital Health
Limited
Founded in 2015, Amiko is growing to become a global provider of hardware enabled, AI powered digital medicines. Amiko’s first product is Respiro, a digital medicine product that upgrades respiratory care using proprietary sensing technology, cognitive computing and elegant digital experiences
is an approved and clinically validated digital medicine product that combines connected inhaler sensors, digital applications, behaviour change programs and predictive analytics to personalize respiratory treatment
Respiro Sensors
Track when and how well patients use their inhalers, and generates personalized inspiration profiles to help monitor disease progression
Respiro Mobile
Drives patient engagement, provides personalized support and coaching, and improves compliance and inhaler technique
Respiro Vision
Guides clinical decisions and offers predictive analytics powered by IBM Xprize awarded AI engine
Respiro is proven to improve adherence, inhaler technique and health outcomes in RCTs and real world settings
Improved adherence
Optimized inhaler technique
Improved symptoms control
1. Chan et al., 2015
2. Sanchis et al., 2016
3. Improvement seen in ACT4Y randomized controlled trial, 2019
Patient interested
in Respiro?
Right now Respiro is only available through healthcare partner programs. Join our mailing list if you want to be contacted when our products are available for sale
Provider interested
in Respiro?
Right now Respiro is only available through healthcare partner programs. If you are interested in a partnership, contact us using the form below
Interested in upgrading
your inhaler product?
Contact us using the form below if you would like to discuss a custom digital medicine for your inhaler product
Latest News
Amiko’s digital prescription intervention service boosts adherence to asthma therapy and health outcomes
Brussels/Milan, BE/IT, 6 May 2019 – The international community is preparing to celebrate World Asthma Day, tomorrow. Asthma is a disease which affects over 300 million people worldwide, a number that is set to rise to 400 million by 2025. Each year, millions of...
Amiko wins open call for innovation of Germany’s largest association of statutory health insurance Physicians
London/Berlin, UK/DE, 1 October 2018 – Amiko announces that its flagship Respiro platform has won the open call for innovation of the German National Association of Statutory Health Insurance Physicians (KBV). Respiro, a digital medicine offering that uses advanced...
Amiko among top three German digital health companies in 2018
London/Berlin, UK/DE, 25 September 2018 – The Heath-I initiative by Handelsblatt and Germany’s largest public health insurance, the Techniker-Krankenkasse nominated Amiko Digital Health for this year’s Health-I Award among the top three companies that have the...
